Healthcare

What Mylan’s CEO learned from the EpiPen outrage

By Paige Winfield Cunningham
Published January 11, 2017 10:26pm ET
Add Washington Examiner on Google
What Mylan’s CEO learned from the EpiPen outrage
Mylan CEO Heather Bresch reflected Wednesday on what she learned from months of public outrage over her company's dramatic price increase for the EpiPen allergy shot. (AP Photo/Pablo Martinez Monsivais) | Pablo Martinez Monsivais

SAN FRANCISCO – Mylan CEO Heather Bresch reflected Wednesday on what she learned from months of public outrage over her company’s dramatic price increase for the EpiPen allergy shot.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Epipen Minusextra Paige Winfield Cunningham Pharmaceutical Industry